| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 283.726 | 244.540 | 207.746 | 162.895 | 188.428 | 246.271 | 246.981 | 349.382 | 301.243 | 739.046 |
| Total Income - EUR | 346.570 | 252.368 | 1.109.096 | 173.958 | 188.866 | 248.384 | 247.136 | 349.523 | 301.688 | 745.676 |
| Total Expenses - EUR | 344.744 | 309.830 | 1.192.995 | 167.312 | 197.657 | 245.781 | 243.947 | 316.133 | 300.634 | 873.505 |
| Gross Profit/Loss - EUR | 1.825 | -57.462 | -83.899 | 6.647 | -8.791 | 2.603 | 3.189 | 33.390 | 1.055 | -127.829 |
| Net Profit/Loss - EUR | -8.243 | -61.422 | -85.535 | 5.073 | -10.679 | 119 | 767 | 29.933 | -1.810 | -127.829 |
| Employees | 4 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 8 |
Check the financial reports for the company - Depomed Eximpharm Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 1.164.434 | 1.166.913 | 7.752 | 5.845 | 4.325 | 3.216 | 2.139 | 1.138 | 12.841 | 47.248 |
| Current Assets | 506.348 | 348.388 | 184.839 | 211.162 | 176.719 | 198.705 | 159.471 | 189.563 | 176.152 | 405.999 |
| Inventories | 14.636 | 15.248 | 18.692 | 22.221 | 21.675 | 29.957 | 26.326 | 27.206 | 46.398 | 191.921 |
| Receivables | 484.244 | 310.056 | 132.995 | 138.700 | 132.356 | 107.833 | 23.338 | 76.647 | 36.921 | 128.076 |
| Cash | 7.469 | 23.083 | 33.152 | 50.241 | 22.688 | 60.914 | 109.807 | 85.710 | 92.833 | 86.002 |
| Shareholders Funds | 537.095 | 470.195 | 155.296 | 157.519 | 143.789 | 141.182 | 115.570 | 92.411 | 61.367 | -66.802 |
| Social Capital | 47 | 47 | 46 | 45 | 44 | 43 | 42 | 43 | 42 | 0 |
| Debts | 1.134.448 | 1.045.545 | 37.314 | 59.568 | 37.554 | 60.812 | 46.164 | 98.407 | 128.193 | 520.570 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Depomed Eximpharm Srl